TORONTO (July 9, 2015) — Xagenic, a molecular diagnostics company developing the lab-free Xagenic X1™ platform for point-of-care use, today announced that it has raised $15 million (CAD). Each of the company's Series B investors has participated in this financing, including Domain Associates, CTI Life Sciences, BDC Capital and the Ontario Capital Growth Corporation.
PE Hub, Cantech Letter, Genome Web, Fierce Medical Devices and the Wall Street Journal's Venture Capital Dispatch blog covered this announcement.
In June, Xagenic also announced it has acquired ...
Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury.
Here's an excerpt (the article only available to BioCentury subscribers):
PCR-based diagnosis of infections can delay treatment decisions by days or hours because the method relies on technical expertise and equipment not available in most point-of-care settings. Xagenic Inc.'s chip-based arrays use a non-PCR, electrochemical approach to diagnose bacterial infections at the point of care in 20 minutes with PCR-like accuracy.
Xagenic's core technology is a silicon chip containing ...
TORONTO (January 30, 2012) – Xagenic Inc., a start-up company created by Dr. Shana Kelley, in partnership with MaRS Innovation, today reached a significant milestone by successfully completing series A financing totaling $10 million.
The financing comes from sources from the private and public sector including CTI Life Sciences Fund L.P., Qiagen N.V. and the Ontario Capital Growth Corporation through its Emerging Technologies Fund. (more…)